CSPC Pharmaceutical Group Gestione
Gestione criteri di controllo 2/4
CSPC Pharmaceutical Group Il CEO è Cuilong Zhang, nominato in May2022, e ha un mandato di 2.5 anni. la retribuzione annua totale è CN¥ 13.47M, composta da 5.1% di stipendio e 94.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.043% delle azioni della società, per un valore di HK$ 25.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 7.7 anni.
Informazioni chiave
Cuilong Zhang
Amministratore delegato
CN¥13.5m
Compenso totale
| Percentuale dello stipendio del CEO | 5.1% |
| Mandato del CEO | 2.5yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | 2.5yrs |
| Durata media del Consiglio di amministrazione | 7.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥5b |
| Jun 30 2024 | n/a | n/a | CN¥6b |
| Mar 31 2024 | n/a | n/a | CN¥6b |
| Dec 31 2023 | CN¥13m | CN¥693k | CN¥6b |
| Sep 30 2023 | n/a | n/a | CN¥6b |
| Jun 30 2023 | n/a | n/a | CN¥6b |
| Mar 31 2023 | n/a | n/a | CN¥6b |
| Dec 31 2022 | CN¥11m | CN¥693k | CN¥6b |
| Sep 30 2022 | n/a | n/a | CN¥6b |
| Jun 30 2022 | n/a | n/a | CN¥6b |
| Mar 31 2022 | n/a | n/a | CN¥6b |
| Dec 31 2021 | CN¥9m | CN¥693k | CN¥6b |
| Sep 30 2021 | n/a | n/a | CN¥6b |
| Jun 30 2021 | n/a | n/a | CN¥6b |
| Mar 31 2021 | n/a | n/a | CN¥5b |
| Dec 31 2020 | CN¥9m | CN¥693k | CN¥5b |
| Sep 30 2020 | n/a | n/a | CN¥4b |
| Jun 30 2020 | n/a | n/a | CN¥4b |
| Mar 31 2020 | n/a | n/a | CN¥4b |
| Dec 31 2019 | CN¥7m | CN¥693k | CN¥4b |
| Sep 30 2019 | n/a | n/a | CN¥4b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥3b |
| Dec 31 2018 | CN¥4m | CN¥298k | CN¥3b |
Compensazione vs Mercato: La retribuzione totale di Cuilong ($USD 1.86M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 735.87K ).
Compensazione vs guadagni: La retribuzione di Cuilong è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Cuilong Zhang (55 yo)
2.5yrs
Mandato
CN¥13,472,000
Compensazione
Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 27.6yrs | CN¥26.68m | 24.16% HK$ 14.4b | |
| Vice-Chairman & CEO | 2.5yrs | CN¥13.47m | 0.043% HK$ 25.6m | |
| Executive Director & Chief Scientist | 6.9yrs | CN¥9.42m | 0.039% HK$ 23.1m | |
| Executive Director | no data | CN¥4.92m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥5.74m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥4.90m | 0.013% HK$ 7.7m | |
| Executive Director | no data | CN¥4.02m | 0.026% HK$ 15.4m | |
| Group Executive President | no data | Nessun dato | Nessun dato | |
| Executive Director | less than a year | Nessun dato | Nessun dato | |
| Executive president & President of Global Research and Development | less than a year | Nessun dato | Nessun dato | |
| Company Secretary | 3.8yrs | Nessun dato | Nessun dato |
2.5yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di 1093 è considerato esperto (durata media dell'incarico 2.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 27.6yrs | CN¥26.68m | 24.16% HK$ 14.4b | |
| Vice-Chairman & CEO | 6.3yrs | CN¥13.47m | 0.043% HK$ 25.6m | |
| Executive Director & Chief Scientist | 6.9yrs | CN¥9.42m | 0.039% HK$ 23.1m | |
| Executive Director | 18.1yrs | CN¥4.92m | 0.013% HK$ 7.7m | |
| Executive Director | 14.1yrs | CN¥5.74m | 0.013% HK$ 7.7m | |
| Executive Director | 12.8yrs | CN¥4.90m | 0.013% HK$ 7.7m | |
| Executive Director | 4yrs | CN¥4.02m | 0.026% HK$ 15.4m | |
| Group Executive President | less than a year | Nessun dato | Nessun dato | |
| Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 3.8yrs | CN¥340.00k | Nessun dato | |
| Independent Non-Executive Director | 11.9yrs | CN¥142.00k | Nessun dato | |
| Independent Non-Executive Director | 8.4yrs | CN¥142.00k | Nessun dato |
7.7yrs
Durata media
54.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1093 sono considerati esperti (durata media dell'incarico 7.7 anni).